Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 2Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Carcinoma, Non-Small-Cell Lung 12Carcinoma, Hepatocellular 9Neoplasm Metastasis 5Stomach Neoplasms 4Biliary Tract Neoplasms 4Neoplasms 3Esophageal Squamous Cell Carcinoma 3Small Cell Lung Carcinoma 2Sarcoma 2Nasopharyngeal Carcinoma 2Lung Neoplasms 2Locally Advanced Rectal Cancer 2Hodgkin Disease 2Head and Neck Neoplasms 2Esophageal Neoplasms 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Breast Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Turcot syndrome 1Triple Negative Breast Neoplasms 1Recurrence 1Plaque, Atherosclerotic 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Overall Survival 1Osteosarcoma 1NSCLC 1

Interventions

Capecitabine 7Irinotecan 5spartalizumab 3Oxaliplatin 3Neoadjuvant Therapy 3Immune Checkpoint Inhibitors 2tislelizumab 1sintilimab 1nimotuzumab 1Radiotherapy 1Radiation 1HMPL-013 1Fluorouracil 1Combined Modality Therapy 1Chemoradiotherapy 1Amifostine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Locally Advanced Rectal Cancer × Immune Checkpoint Inhibitors × Clear all
NCT06304987 2024-03-19

Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and PCSK9 Inhibitor for pMMR/MSS Locally Advanced Mid-low Rectal Cancer

Beijing Friendship Hospital

Phase 2 Unknown
50 enrolled
Gastrointestinal

Locally Advanced Rectal Cancer

NCT05845268 2023-05-06

Total Neoadjuvant Therapy Combined With Tislelizumab for Local Advanced of Middle and Low Rectal Cancer

Beijing Friendship Hospital

Phase 2 Unknown
102 enrolled
Gastrointestinal

Locally Advanced Rectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡